3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
27
Leukemia, Myeloid, Acute
27
Leukemia
16
Myelodysplastic Syndromes
13
Multiple Myeloma
9
Neuroblastoma
5
Melanoma
5
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Uterine Cervical Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Thrombocytopenia
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled